Minova Life Science

Minova life sciences - Pharmaceutical company


As Bacteria Get Tougher



Amoxycillin 250/500 mg + Clavulanic acid 125 mg


  • Acute bacterial sinusitis
  • Acute exacerbations of chronic bronchitis
  • Community-acquired pneumonia
  • Pyelonephritis
  • SSTI
  • Acute otitis media
  • Cystitis
  • Bone & joint infections



  •  Clavulanic acid is a potent inhibitor of B-lactamase but shows minimal antibacterial action.
  •  Clavulanic acid prevents amoxicillin from being degraded by B-lactamase thus extended its spectrum of activity against organisms which would normally resistant to amoxicillin alone.
  • Shows good oral absorption & broad spectrum activity.
  •  Cover broader range of organisms in the treatment of facial and periorbital cellulitis than flucloxacillin.
  • Shows good kidney penetration in treatment of acute pyelonephritis.
  •  Provides more than 70% cure rates in amoxicillin resistant bacteria in UTI.

Explore other products

Scroll to Top